100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Pharmacoepidemiology - summary of all lectures $7.38   Add to cart

Summary

Pharmacoepidemiology - summary of all lectures

 4 views  0 purchase
  • Course
  • Institution

Summary off all the lectures of the pharmacoepidemiology course at the Rijksuniversiteit Groningen.

Preview 4 out of 33  pages

  • August 30, 2024
  • 33
  • 2022/2023
  • Summary
avatar-seller
Pharmacoepidemiology
Lecture 1: Pharmacoepidemiology, Introduction (E. Hak)

Clinical questions:
1. DIAGNOSTICS: What is wrong?
2. ETIOLOGY: What is the cause
3. PROGNOSIS: What is the future of this patient?
4. INTERVENTION/THERAPY: What is the best treatment/how to prevent?
5. EFFICIENCY/ECONOMICS: How much does it cost?

Epidemiology: studies the occurrence of diseases in large populations of people as a function of
determinants. Epidemiology is an essential science for the conduct of ‘Evidence Based Medicine’.




Vaccination rate required is 94%

Process of drug development:
Drug discovery; how should the vaccine be made  characterisation  formulation; how to produce
at large quantities  pre-marketing clinical trials; registration  post-marketing
pharmacoepidemiologic studies  economical evaluation.

Pharmaco-epidemiology: studies the contribution of drugs in disease prevention and therapy in large
populations.

Main reasons for dangerous side effects and withdrawal:
1. Clinical trials are not large.
2. Real world use of a drug differs  trials are done in healthy people whereas the users will be
severely diseased.
3. Time plays a role  trials have short duration while for some drugs you should use it for a
long time before a disease pops up.
4. Off-label prescribing may bring up unexpected issues  e.g. for children.

Drug repurposing: drugs made for a disease have a positive effect on something else  drug is used
for not for the initial purpose.




1

,Typical post marketing research questions:




Drug X = the outcome of the study question. Patient Y = the study domain/hypothetical patient. Age
and sex are the determinants of the outcome.




Drug X = the determinant. Outcome Y = outcome. Disease Z = the study domain/hypothetical patient.

Types of epidemiological studies:
- Experimental studies: investigator determines what the participant is going to get.
 RCT’s / community intervention trials / field trials.
- Observational studies: investigator has no influence on whether you get your vaccine.
 Descriptive studies / case-control studies / cohort studies.

Randomised Control Trials (RCT):
- Narrow indications  you want everyone to have the drug registered for a certain indication.
- Homogeneous population  no people who with risks to avoid side effects.
- Small number trials  not more than 5000.
- Randomisation  computer determines who gets the vaccine or not, to avoid placebo.
- Double blinding  patients and doctors don’t know who has the drug/placebo.
- Relatively short-term therapy  trials are very expensive.
All of these trials lead to Evidence Based Medicine.

Observational trials (post marketing surveillance PMS
- Large numbers of patients
- Unlimited time of therapy.
- Drug-users in practice.
- Other influences (smoking, other drugs, nutrition)

RCTs is a really small part of the total patient population that is present. Whereas if you go to the
drug (post marketing) there is a much wider variation of people that is using it.

Important clinical information that has to be obtained in PMS research
- Usage and determinants in practice.
- Effects in daily practice (when combining with smoking/alcohol).
- Adverse effects.
- Drug interactions.
- New applications.
- Usage of the drug for other indications.
- Applied dosage and duration.
- Usage/effect in children/elderly and pregnant woman.
- Effect on hard endpoints (disease/mortality)
- Effect on population level.
- Costs.
- Compliance.
- Cost-effectiveness of interventions.

2

,Terminology:
- Efficacy: effect in clinical trials or laboratory situations.
- Effectiveness: effect in daily practice.
- Efficiency: costs in relations to effects.

Post marketing surveillance (PMS): phase-IV study that monitors all desirable and undesirable
effects of drugs to human health, after these drugs are released on the market. The goal is to obtain
scientifically based data on rational and safe use of drugs.

Who has interest in PMS?:
- Patient  wants effective and safe drug with reliable information.
- Physician/pharmacist  wants reliable and complete information to make a good decision.
- Insurance company  importance of rational prescribing with regard to costs.
- Government  registration and safety.
- Industry  wants a good product.

Data sources for PMS:
- Spontaneous reporting systems.
 Pharmacovigilance database Lareb  pharmacists report any adverse effect that has
not been mentioned earlier.
- Routine databases (prescription/GP database).
- Questionnaires/interviews/web-based.
- Cohorts/physical testing/lab data.

Algemene verordering gegevensbescherming (AVG) / General Data Protection Regulation (GDPR):
privacy law that makes it much harder to get medical data from a patient (2018).

Pharmlines Initiative: to link the lifelines cohort study to the prescription data base IADB.
It does not matter much whether you take information from the GP or from the questionnaire 
both resulted in more or less the same odds ratio.

ATC (Anatomical Therapeutic Chemical) system.
- Classification is done each year by the WHO. There are 7 positions and 5 hierarchical levels.
- e.g. N05BA01
- Coding can be different for the same drug  different dosage forms.
Level 1: 1 letter  anatomical main group.
Level 2: 2 digits  therapeutic main group.
Level 3: 1 letter  therapeutic subgroup.
Level 4: 1 letter  therapeutic/chemical subgroup.
Level 5: 2 digits  chemical substance.




3

, Defined daily dose (DDD): average daily maintenance dose for a drug used for it’s main indication in
adults. Mainly used to quantify the volume of drug usage at the population level.
- Based on final phase registration trial just before registration.
- DDD does not contain patient information  rough estimate.
- May vary by country.
- DDD of new drugs is revised after 3 years.

DDD lower than 1  the drug is not as effective as it should be.
DDD higher than 1  side effects.

Lareb: spontaneous reporting method.
- Things are reported such as: new adverse effects, severe adverse effects and new drugs.
- Pharmacists are the most importing cases into Lareb.
- Lareb will determine if there is a causal relation between the drug and the side effect. For
each report they make a causal association to determine whether a side effect is caused by
the drug or not.
- Naranjo algorithm: list of questions that give + of – points. Used for individual cases.

Bias in spontaneous reporting systems:
- Weber effect a drug that is new on the market leads to many adverse reports  just because
it is new.
- Channeling phenomenon  when drug therapies with similar indications are preferentially
prescribed to groups of patients with varying baseline prognoses.

Cohort studies advantages are:
- Fast.
- Large numbers.
- Validation data.
- Prevents recall bias.
- Information about reference group or controls without disease.
- Low costs.
- Minimal effort for the researcher.

Disadvantages of many observational studies:
- Indication bias.
- Insufficient number of patients.
- New drug (channeling).
- No information about confounding variables.
- Validity and completeness of data is dependent on the data source.




4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller sarahwierda. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $7.38. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

79751 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$7.38
  • (0)
  Add to cart